Tenomix is focused on revolutionizing the pathology workflow, particularly in the context of colorectal cancer diagnosis and treatment. Their flagship technology, The Lymphonator, is an innovative bench-top robotic scanning device designed to automate the identification of lymph nodes in surgically removed colorectal cancer tissues. This device addresses the inefficiencies of the current manual search process, which is labor-intensive and prone to human error, particularly in detecting smaller lymph nodes that may be critical for accurate cancer staging and treatment. By utilizing advanced imaging modalities, The Lymphonator can reliably identify lymph nodes smaller than 5 mm, significantly improving detection rates compared to traditional methods.

The Lymphonator not only enhances the accuracy of lymph node identification but also streamlines the workflow for pathology staff. Its "set-and-forget" feature allows medical professionals to engage in other clinical duties while the device automatically scans and marks lymph nodes for extraction. This integration into existing clinical workflows minimizes disruption and maximizes efficiency, ultimately leading to reduced costs for pathology departments and better patient outcomes. By improving the reliability and speed of lymph node detection, Tenomix aims to support healthcare providers in making more informed treatment decisions, thereby enhancing the overall quality of cancer care.

Canada

Tenomix is a medical technology company focused on developing novel technologies to target inefficiencies in the pathology workflow and optimize cancer care. Their vision is to be at the forefront of pathology innovation, ensuring pathology staff are equipped with the right tools that help in battling cancer. Tenomix has also secured significant funding for their innovative solutions in cancer care.

Tenomix

Company Details